Rulli Rosandi, Herman Bagus Trianto, Aywar Zamri, Harli Amir, Roy Panusunan Sibarani, Samuel Sulaiman, Achmad Rudijanto Cholil
Background: Type 2 diabetes mellitus (T2DM) is considered one of the top 3 causes of death in Indonesia. However, the current scenario regarding the management of T2DM in Indonesia remains unclear. Thus, the present study aimed to describe the baseline characteristics, treatment types, and quality of care indicators in T2DM patients under the DISCOVER CaReMe Registry program. Methods: DISCOVER CaReMe Registry program is a multi-centre, prospective, and observational study conducted over 3 years from 2018-2021. The data were collected from five different sites across Indonesia. Results: A total of 539 patients with a mean age of 58.98 ± 9.76 were enrolled in the study. Among them, 62% (334/539) of patients were females. Further, the mean glycated haemoglobin (HbA1c) levels were 8.54 ± 2.88%, which was much higher than the American Diabetes Association (ADA) recommended target of 7%. Overall, 69% of the patients had HbA1c levels of >7%. First-line treatment in patients was mostly metformin (26%). As per the quality-of-care indicators, 72.2% of patients use glucose monitoring equipment and receive education about diabetes treatment and management. Furthermore, the knowledge of T2DM among patients was assessed in over 85% of cases, and misconceptions about the condition were clarified by healthcare professionals (HCPs). HCP advised a “diabetic diet” to 69.4% of patients. Conclusion: Despite a good knowledge and quality of care indices in patients with T2DM, the proportion of patients with HbA1c levels of >7% is still higher. There is an urgent need for diabetic management programs to prevent such complications in the Indonesian population. © 2025, Indonesian Society of Internal Medicine. All rights reserved.
Department of Internal Medicine, Universitas Brawijaya, Malang, Indonesia; IHC Perkebunan Jember Klinik Hospital, East Java, Indonesia; Faculty of Medicine and Health Sciences, Jambi University, Indonesia; Department of Internal Medicine, Prof. Dr. Soerojo Mental Hospital, Magelang, Indonesia; EMC Hospital, Sentul, Bogor, Indonesia; AstraZeneca, Indonesia
